Follow
Tomasz M. Beer
Tomasz M. Beer
Exact Sciences Corporation and Oregon Health & Science University
Verified email at ohsu.edu
Title
Cited by
Cited by
Year
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
33602014
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
C Tran, S Ouk, NJ Clegg, Y Chen, PA Watson, V Arora, J Wongvipat, ...
Science 324 (5928), 787-790, 2009
26782009
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
24362008
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
15742014
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
14512021
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
13262016
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
The Lancet 375 (9724), 1437-1446, 2010
13102010
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
Y Sun, J Campisi, C Higano, TM Beer, P Porter, I Coleman, L True, ...
Nature medicine 18 (9), 1359-1368, 2012
8572012
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
854*2018
Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant …
TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ...
Journal of Clinical Oncology 35 (1), 40-47, 2017
7322017
Genomic hallmarks and structural variation in metastatic prostate cancer
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
6482018
Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ...
Journal of Clinical Oncology 36 (24), 2492, 2018
6122018
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
EK Fromme, KM Eilers, M Mori, YC Hsieh, TM Beer
Journal of Clinical Oncology 22 (17), 3485-3490, 2004
6022004
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
SF Slovin, CS Higano, O Hamid, S Tejwani, A Harzstark, JJ Alumkal, ...
Annals of Oncology 24 (7), 1813-1821, 2013
5882013
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
4632017
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer
ML Zhu, CM Horbinski, M Garzotto, DZ Qian, TM Beer, N Kyprianou
Cancer research 70 (20), 7992-8002, 2010
4182010
Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer
AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ...
JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017
3972017
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
JN Graff, JJ Alumkal, CG Drake, GV Thomas, WL Redmond, M Farhad, ...
Oncotarget 7 (33), 52810, 2016
3812016
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT …
TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, ...
Journal of Clinical Oncology 25 (6), 669-674, 2007
3802007
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3792015
The system can't perform the operation now. Try again later.
Articles 1–20